Dx Deals: Labcorp Acquires Stake in European Testing Giant
$152.1 million SYNLAB deal is expected to create a new channel for Labcorp to market its sophisticated specialty assays
Laboratory Industry Report
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Subscribe today for access to
Articles and Reports
Fighting the FDA’s Final Rule on LDTs
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.
Is Sales Training Really Needed in the Lab Industry?
Why ongoing coaching and learning is required for laboratory sales reps—even experienced ones—to help labs meet their business goals
Finding the “Backdoor” into Payer Networks
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
New overtime rule now in effect
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
The DX Pipeline: New Invitae App Leverages Apple Watch Data for Studying Disease Genetics
Invitae’s newly launched Invitae Discover app is in many ways the perfect manifestation of where consumer-based precision medicine diagnostics is heading. The app combines health and activity data from Apple Health and the
FDA Watch: Agency Targets Sale of IVD Reagents without Premarket Approval
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Industry Buzz: The 10 Biggest DX Mergers of 2019
Conspicuous by its absence from the list is the proposed $1.2 billion Illumina takeover of Pacific Biosciences which suddenly seems to be in major trouble. Here are the 10-highest value M&A diagnostics deals that did come off in 2019.
Accessions Disappearing or Not Getting Billed?
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Genetic Testing: New Medicare Early NGS Cancer Test Coverage Policy Is Less than Meets the Eye
For Myriad Genetics, Foundation Medicine and other manufacturers of next-generation sequencing (NGS)-based test panels for early-stage cancer risk assessment, the recent announcement of CMS’ decision to provide limited Medicare coverage
5 ways to break down bureaucracies to get payer contracts
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Diagnostic Deals: Illumina/PacBio Merger Derails & Qiagen Takes Itself Out of Play
As 2019 came to a close, the biggest story in DX deal making was the pair of anticipated M&A deals that suddenly seem unlikely to happen. As a result, two major genetic testing companies will apparently continue as stand-alones in the coming year, one because it wants to and the other because it has to.
The DX Pipeline: A roundup of the month’s key new product launches
The last quarter is typically the busiest of the year for new product launches and 2019 is no exception. The DX pipeline was churning at a high pace from late October to mid-November. Here’s a rundown of the key product launches